Q3 2024 Arcticzymes Technologies ASA Earnings Call Transcript
Good morning and welcome to Arcticzymes Q3 earnings report. My name is Michael B. Akoh. I'm the CEO of Arcticzymes and as usual, I'm joined by Børge Sørvoll, our CFO a quick look at the agenda and what we're going to cover today, we're going to share some highlights from the quarter. Then we're going to be talking about the commercial transformation that we're currently going through as well as the next stage of that commercial transformation. And I'm going to touch upon our strategic priorities and then I'm going to follow up with a look into sales for the quarter and then the biomanufacturing updates in regards to agreements. And then I look into the future in regards to our coming portfolio. Then Borge is going to take over and go into the financials. And finally, we're going to take questions.
There's no doubt about that Q3 was a challenging quarter in terms of revenue. We made a NOK24.1 million and it was in particular, the molecular tools segment that had a soft quarter that also is reflected in the EBITDA numbers where we had a loss of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |